When given alongside chemotherapy, Tecentriq (atezolizumab) increases the percentage of people with early triple-negative breast cancer (TNBC) who show no signs of cancer during tumor removal surgery, a Phase 3 trial shows. These results were found regardless of the patient’s PD-L1 status, or the amount of the PD-L1 protein on the individual’s cancer cells. The study, called IMpassion031 (NCT03197935), is the second Phase 3 trial carried out by Genentech showing the benefits of Tecentriq for people…
You must be logged in to read/download the full post.
The post Tecentriq-Chemo Combo Ups Percentage of TNBC Patients With No Cancer at Surgery appeared first on BioNewsFeeds.